Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2007

01-03-2007 | Concise Article

Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro

Authors: E. Caraher, G. Reynolds, P. Murphy, S. McClean, M. Callaghan

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2007

Login to get access

Abstract

This study determined the antibiotic susceptibility of planktonic and biofilm cultures of Burkholderia cepacia complex organisms, a group of highly problematic pathogens associated with cystic fibrosis patients. The biofilm inhibitory concentrations were considerably higher than the corresponding minimum inhibitory concentrations for meropenem and piperacillin-tazobactam. However, tobramycin and amikacin were efficacious against both biofilm and planktonic cultures. Overall this study showed that biofilm susceptibility testing might be more clinically appropriate for determining antibiotic therapy for Burkholderia cepacia complex infections in cystic fibrosis patients.
Literature
1.
Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H (1984) Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 104:206–210PubMedCrossRef
2.
LiPuma JJ, Spilker T, Gill LH, Campbell PW 3rd, Liu L, Mahenthiralingam E (2001) Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 164:92–96PubMed
3.
Burns JL, Jonas M, Chi EY, Clark DK, Berger A, Griffith A (1996) Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun 64:4054–4059PubMed
4.
Schwab U, Leigh M, Ribeiro C, Yankaskas J, Burns K, Gilligan P, Sokol P, Boucher R (2002) Patterns of epithelial cell invasion by different species of the Burkholderia cepacia complex in well-differentiated human airway epithelia. Infect Immun 70:4547–4555PubMedCrossRef
5.
Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167–193PubMedCrossRef
6.
Moskowitz SM, Foster JM, Emerson J, Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42:1915–1922PubMedCrossRef
7.
Desai M, Buhler T, Weller PH, Brown MR (1998) Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxacin and ceftazidime during exponential growth. J Antimicrob Chemother 42:153–160PubMedCrossRef
8.
Tomlin KL, Malott RJ, Ramage G, Storey DG, Sokol PA, Ceri H (2005) Quorum-sensing mutations affect attachment and stability of Burkholderia cenocepacia biofilms. Appl Environ Microbiol 71:5208–5218PubMedCrossRef
9.
Kalish LA, Waltz DA, Dovey M, Potter-Bynoe G, McAdam AJ, Lipuma JJ, Gerard C, Goldmann D (2005) Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 173:421–425PubMedCrossRef
10.
Caraher E, Duff C, Mullen T, Mc Keon S, Murphy P, Callaghan M, McClean S (2007) Invasion and biofilm formation of Burkholderia dolosa is comparable with Burkholderia cenocepacia and Burkholderia multivorans. J Cyst Fibros 6:49–56PubMedCrossRef
11.
Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48:3670–3676PubMedCrossRef
12.
Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R (2002) Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 40:4172–4179PubMedCrossRef
13.
Hodson ME, Gallagher CG, Govan JR (2002) A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20:658–664PubMedCrossRef
14.
Saika T, Kobayashi I, Hasegawa M, Nishida M (2002) Antimicrobial resistance and DNA-fingerprinting pattern of Burkholderia cepacia blood isolates. J Infect Chemother 8:341–344PubMedCrossRef
15.
Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S (2006) Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PA01: a global approach. Antimicrob Agents Chemother 50:1680–1688PubMedCrossRef
Metadata
Title
Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro
Authors
E. Caraher
G. Reynolds
P. Murphy
S. McClean
M. Callaghan
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0256-x

Other articles of this Issue 3/2007

European Journal of Clinical Microbiology & Infectious Diseases 3/2007 Go to the issue

Article

Extended-spectrum β-lactamase-producing Shigella strains in Israel, 2000–2004

Article

Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999–2004

Concise Article

Two outbreaks of acute hemorrhagic conjunctivitis in Africa due to genotype III coxsackievirus A24 variant

Article

Selective ambulatory management of imported falciparum malaria: a 5-year prospective study

Concise Article

Comparison of PCR, microscopic examination and culture for the early diagnosis and characterization of Acanthamoeba isolates from ocular infections

Article

Imported malaria at Italy’s National Institute for Infectious Diseases Lazzaro Spallanzani, 1984–2003
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits